Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -
Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram
Important Resources for the MS community are found on the left side of this blog.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, March 8, 2014
Stairs posed a major barrier for disabled people in wheelchairs. A new Israeli technology is changing the rules of the game. bomber survives his attempted terrorist attack and arrives at a hospital next to his victims. In any other country, this script may seem to be totally fictional, however, in Israel; this cinematic concept is based on reality.
Mar 08, 2014, | Linda Lovitch
Until now, stairs posed a major barrier for disabled people in wheelchairs. A new Israeli technology is changing the rules of the game. Daniel Barel, the CEO explains, “Softwheel gives the freedom to get off the pavement , road, or staircase without using a ramp." The technology absorbs the shock when the wheelchair is lowered from one level to another.
Watch a video of this new technology and read more by clicking here: http://www.jerusalemonline.com/culture-and-lifestyle/new-invention-gives-disabled-a-smooth-ride-down-stairs-4125
Friday, March 7, 2014
ENDECE Neural to Present Updated Data at ASN Annual Meeting Showing NDC-1308 Induces Remyelination in Multiple Sclerosis (MS)
The MS ATRIUM website has added MS Views and News to their resources page. To see this page and to use the MS Atrium website visit:
Sunday, March 2, 2014
Feeling the MS blues? Banish that bad mood with these treatment tactics.
To comment - click the comment link shown below
Share our Articles with others
Share our Articles with others
Lemtrada Update: First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada
LEMTRADA 12 mg has a dosing and administration schedule of two annual treatment courses. The first treatment course of LEMTRADA is administered via intravenous infusion on five consecutive days, and the second course is administered on three consecutive days, 12 months later. LEMTRADA patients require monitoring at regular intervals between treatment courses and for 48 months following the final infusion.
During an extensive, ongoing clinical development program, 80 per cent of RRMS patients who received two treatment courses of LEMTRADA required no further therapy1 and 55 per cent remained relapse-free through the first year of the extension study. Unlike other current disease modifying therapies (DMTs) in which stopping treatment usually results in resumed disease activity, LEMTRADA continues to have a durable effect far beyond the two annual treatment courses. In fact, in more than 70 per cent of clinical trial patients, disability scores improved or remained stable over three years.1
"The approval of LEMTRADA represents an important new treatment option for Canadians living with MS. In clinical trials, LEMTRADA demonstrated impressive effectiveness following two treatment courses for patients with active relapsing MS," said Dr. Anthony Traboulsee, Associate Professor of Neurology and Medical Director of the UBC Hospital MS Clinic of Vancouver Coastal Health. "Our own experience in treating 35 patients through clinical trials with LEMTRADA has been extremely positive."
LEMTRADA was approved by Health Canada in December 2013. The approval was based on data from the LEMTRADA clinical development program comparing treatment of LEMTRADA to high-dose subcutaneous interferon beta-1a (Rebif®) - which is dosed three times per week - in patients with RRMS who had active disease. In a controlled Phase 3 clinical study, LEMTRADA was more effective compared to Rebif at reducing both the annualized relapse rates (ARR) and the accumulation of disability was significantly slowed in patients given LEMTRADA vs. Rebif.2
In clinical trials, LEMTRADA demonstrated an ARR reduction of 49.4 per cent when compared with Rebif (p<0.0001), and the proportion of relapse-free patients was significantly (p<0.0001) higher in LEMTRADA patients than Rebif (65.4 per cent and 46.7 per cent, respectively). In addition, the risk of sustained accumulation of disability (SAD) over six months was reduced by 42 per cent in patients who received LEMTRADA versus Rebif (p=0.0084).2
"The approval and availability of LEMTRADA represents an important advancement for the MS community," said Dr. Karen Lee, Vice-President, Research, Multiple Sclerosis Society of Canada. "The more treatment options that are available, the more choices Canadians living with MS have to potentially improve their overall quality of life."
In November 2013, Genzyme's AUBAGIO® (teriflunomide) 14 mg was approved by Health Canada as monotherapy for the treatment of patients with RRMS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. The approval was based on efficacy data from two Phase III clinical trials - TEMSO (TEriflunomide Multiple Sclerosis Oral) and TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis). In the TEMSO trial, AUBAGIO 14 mg significantly reduced the annualized relapse rate (p=0.0005) and the time to disability progression (p=0.0279) at two years versus placebo in patients with RRMS. In the TOWER trial, AUBAGIO 14 mg significantly reduced the annualized relapse rate (p=0.0001) and the time to disability progression sustained for 12 weeks (p=0.0442) was statistically significantly reduced versus placebo in patients with RRMS.
"The Canadian approval and availability of LEMTRADA and AUBAGIO represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to MS patients," said Peter Brenders, General Manager, Genzyme Canada. "We are proud of our commitment to long-term leadership and partnership with the MS community."
LEMTRADA is supported by a comprehensive and extensive clinical development program that involved 1,188 patients, resulting in 2,363 patient-years of safety follow-up.
A New Standard in Patient Support
Complete story found here: http://www.digitaljournal.com/pr/1762094#ixzz2upmX4zaY